Association between interleukin-12 p40 subunit and risk of primary Sjögren’s disease: a Mendelian randomization study

TY - JOUR

T1 - Association between interleukin-12 p40 subunit and risk of primary Sjögren’s disease

T2 - a Mendelian randomization study

AU - Zuckerman, Benjamin P.

AU - Yang, Zijing

AU - Warwick, Alasdair

AU - Wincup, Chris

AU - Russell, Mark D.

AU - Galloway, James B.

AU - Zhao, Sizheng Steven

N1 - Publisher Copyright: © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

PY - 2024/9/2

Y1 - 2024/9/2

N2 - Objectives: IL-12 signalling was proposed in the immunopathogenesis of primary Sjögren’s disease. The efficacy of therapies targeting this pathway is currently unclear. Herein, we investigated the associations between circulating proteins involved in the IL-12 and IL-23 signalling pathways on primary Sjögren’s disease using Mendelian randomization. Methods: We selected single nucleotide polymorphisms from protein quantitative trait loci of IL12A, IL12B, IL12Rβ1, IL12Rβ2 and IL23R to examine the association between alterations in their levels and risk of primary Sjögren’s disease. Genetic association data for proteins were taken from studies ranging from 3301 to 54 306 in sample size, and from 3232 cases of primary Sjögren’s disease and 17 481 controls. The Wald ratio or inverse variance weighted methods estimated causal effects. We applied colocalization and pleiotropy-robust methods as sensitivity analyses for confounding. Results: There was a negative association between genetically predicted IL-12p40 (encoded by IL12B) and primary Sjögren’s disease. In the two independent exposure datasets odds ratio (OR), 0.79 (95% CI 0.68–0.93; P-value ¼ 0.004) and OR 0.86 (95% CI 0.78–0.95; P-value ¼ 0.003) per S.D. decrease in genetically predicted IL-12p40. Neither IL-12Rβ2 nor IL-23R met the threshold P-value after Mendelian randomization analyses (P-value < 0.01) for colocalization assessment. No variants for the IL12A gene met prerequisite thresholds for weak instrument bias. Conclusion: This study provides genetic evidence that IL-12p40 has a causal role in primary Sjögren’s disease pathogenesis. Our data suggest that decreasing levels of IL-12p40 may be deleterious. We would not suggest selecting this drug target as a therapeutic option.

AB - Objectives: IL-12 signalling was proposed in the immunopathogenesis of primary Sjögren’s disease. The efficacy of therapies targeting this pathway is currently unclear. Herein, we investigated the associations between circulating proteins involved in the IL-12 and IL-23 signalling pathways on primary Sjögren’s disease using Mendelian randomization. Methods: We selected single nucleotide polymorphisms from protein quantitative trait loci of IL12A, IL12B, IL12Rβ1, IL12Rβ2 and IL23R to examine the association between alterations in their levels and risk of primary Sjögren’s disease. Genetic association data for proteins were taken from studies ranging from 3301 to 54 306 in sample size, and from 3232 cases of primary Sjögren’s disease and 17 481 controls. The Wald ratio or inverse variance weighted methods estimated causal effects. We applied colocalization and pleiotropy-robust methods as sensitivity analyses for confounding. Results: There was a negative association between genetically predicted IL-12p40 (encoded by IL12B) and primary Sjögren’s disease. In the two independent exposure datasets odds ratio (OR), 0.79 (95% CI 0.68–0.93; P-value ¼ 0.004) and OR 0.86 (95% CI 0.78–0.95; P-value ¼ 0.003) per S.D. decrease in genetically predicted IL-12p40. Neither IL-12Rβ2 nor IL-23R met the threshold P-value after Mendelian randomization analyses (P-value < 0.01) for colocalization assessment. No variants for the IL12A gene met prerequisite thresholds for weak instrument bias. Conclusion: This study provides genetic evidence that IL-12p40 has a causal role in primary Sjögren’s disease pathogenesis. Our data suggest that decreasing levels of IL-12p40 may be deleterious. We would not suggest selecting this drug target as a therapeutic option.

KW - IL-12

KW - Mendelian randomization

KW - Sjögren’s disease

UR - http://www.scopus.com/inward/record.url?scp=105001981697&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keae475

DO - 10.1093/rheumatology/keae475

M3 - Article

C2 - 39222420

AN - SCOPUS:105001981697

SN - 1462-0324

VL - 64

SP - 2295

EP - 2299

JO - Rheumatology

JF - Rheumatology

IS - 4

ER -